These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 26415231)

  • 1. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
    Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G
    Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma cancer stem cells.
    Gao M; Kong Y; Yang G; Gao L; Shi J
    Oncotarget; 2016 Jun; 7(23):35466-77. PubMed ID: 27007154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cancer stem cells in multiple myeloma.
    Gunes EG; Gunes M; Yu J; Janakiram M
    Trends Cancer; 2024 Aug; 10(8):733-748. PubMed ID: 38971642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway.
    Wang H; Gong Y; Liang L; Xiao L; Yi H; Ye M; Roy M; Xia J; Zhou W; Yang C; Shen X; Zhang B; Li Z; Liu J; Zhou H; Xiao X
    Br J Haematol; 2020 Jun; 189(6):1151-1164. PubMed ID: 32167591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
    Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
    Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
    Matsui W; Wang Q; Barber JP; Brennan S; Smith BD; Borrello I; McNiece I; Lin L; Ambinder RF; Peacock C; Watkins DN; Huff CA; Jones RJ
    Cancer Res; 2008 Jan; 68(1):190-7. PubMed ID: 18172311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.
    Yi H; Liang L; Wang H; Luo S; Hu L; Wang Y; Shen X; Xiao L; Zhang Y; Peng H; Dai C; Yuan L; Li R; Gong F; Li Z; Ye M; Liu J; Zhou H; Zhang J; Xiao X
    Cancer Lett; 2021 Nov; 520():307-320. PubMed ID: 34390764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stem cells in multiple myeloma.
    Ghosh N; Matsui W
    Cancer Lett; 2009 May; 277(1):1-7. PubMed ID: 18809245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
    Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S
    Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718
    [No Abstract]   [Full Text] [Related]  

  • 10. The myeloma stem cell concept, revisited: from phenomenology to operational terms.
    Johnsen HE; Bøgsted M; Schmitz A; Bødker JS; El-Galaly TC; Johansen P; Valent P; Zojer N; Van Valckenborgh E; Vanderkerken K; van Duin M; Sonneveld P; Perez-Andres M; Orfao A; Dybkær K
    Haematologica; 2016 Dec; 101(12):1451-1459. PubMed ID: 27903712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
    Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
    Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concise review: Defining and targeting myeloma stem cell-like cells.
    Abe M; Harada T; Matsumoto T
    Stem Cells; 2014 May; 32(5):1067-73. PubMed ID: 24449391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
    Gooding S; Edwards CM
    Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Multiple Myeloma Cancer Stem Cells with Natural Products - Lessons from Other Hematological Malignancies.
    Issa ME; Cretton S; Cuendet M
    Planta Med; 2017 Jun; 83(9):752-760. PubMed ID: 28472843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
    Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
    Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage Inhibitory Factor-1 (MIF-1) controls the plasticity of multiple myeloma tumor cells.
    Joseph D; Gonsky JP; Blain SW
    PLoS One; 2018; 13(11):e0206368. PubMed ID: 30383785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.
    Blatt K; Herrmann H; Stefanzl G; Sperr WR; Valent P
    Oncotarget; 2016 Oct; 7(40):65627-65642. PubMed ID: 27582537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fact or fiction--identifying the elusive multiple myeloma stem cell.
    Kellner J; Liu B; Kang Y; Li Z
    J Hematol Oncol; 2013 Dec; 6():91. PubMed ID: 24314019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
    Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
    Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.